HOME >> BIOLOGY >> NEWS
Mayo Clinic researchers enhance safety and effectiveness of therapeutic virus that fights cancer

Rochester, Minn. -- Mayo Clinic researchers working with colleagues in Germany have devised a much-needed multilevel safety feature for viruses used to treat cancer. In the process of making cancer-killing viruses more specific to cancer tumor cells, they report having improved the therapeutic effectiveness of viruses. They did this by engineering a modified measles virus that turns on only in the presence of secretions specific to malignant cancer cells.

In effect, the Mayo Clinic virus makeover uses proteins secreted by cancer cells as the unique key to the virus' ignition. Their report on the topic appears in the Aug. 1 edition of Cancer Research (http://cancerres.aacrjournals.org).

The investigation was performed in laboratory mice that were transplanted with a human cancer. The process is still experimental -- and thus, years away from clinical use in humans. However, the Mayo results may be immediately useful in designing improved cancer treatments for humans. "Our work shows that oncolytic measles virus particle activation can be made dependent on substances secreted by cancer cells, and this enhances safety," explains Roberto Cattaneo, Ph.D., lead researcher on the Mayo team. "By doing this, our study broadens the safeguarding strategies possible to tightly restrict the targeted virus to cancer cells."

Significance of the Mayo Clinic Research
The Mayo researchers say their contribution is a key advance because it provides a method of designing a therapeutic virus that is safe, stable and that reliably targets and kills cancer cells. Importantly, it appears to greatly reduce the possibility that the virus would erroneously turn on and harm the patient by causing unintended infection.

As such, the Mayo innovation of the cancer-activated virus is a helpful safety advance for the promising experimental field of "oncolytic virotherapy." The phrase refers to t
'"/>

Contact: Bob Nellis
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
1-Aug-2006


Page: 1 2

Related biology news :

1. 2007-2008 Genzyme/ACMGF Clinical Genetics Fellowship In Biochemical Genetics award winner announced
2. Scientists honored with Excellence in Clinical Research Award
3. Clinical trial data regarding NKTR-061 will be presented at ATS International Conference
4. NIH awards VBI, Mayo Clinic $2.4M to study chronic rhinosinusitis
5. Clinical trial for diabetic macular edema
6. The Parkinsons Institute to conduct Phase III Clinical Trial of creatine for Parkinsons disease
7. Research and program highlights of the 2007 Annual Clinical Genetics Meeting, March 21-25, 2007
8. Arizona State University and Mayo Clinic join forces to develop cancer vaccine
9. Marshfield Clinics electronic health record first to receive CCHIT certification
10. American College of Medical Genetics -- 2007 Annual Clinical Genetics Meeting Announcement
11. October MCP: A special issue on Clinical Proteomics

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/10/2020)... ... July 08, 2020 , ... Overcoming Comparability Issues in Regenerative ... Webinar, Wednesday, July 22, 2020 • 1:30 p.m.-3:00 p.m. EDT, https://www.fdanews.com/cellandgenetherapy ... effective way to complete one? Will the study comply with all FDA requirements? ...
(Date:7/2/2020)... Calif. (PRWEB) , ... July 01, 2020 , ... ... company, presented its phase 1a findings of Neihulizumab, a biologic for the treatment ... in June 2020. Led by hemato-oncologist Dr. Paul J Martin of the Fred ...
(Date:7/1/2020)... VENICE, Calif. (PRWEB) , ... July 01, 2020 ... ... focused on building awareness and solutions for glioblastoma—the most common and aggressive adult ... and Lisa Haile, JD, PhD. Senior Fellows are charged with supporting the organization’s ...
Breaking Biology News(10 mins):
(Date:7/10/2020)... HONG KONG (PRWEB) , ... July 09, 2020 ... ... chemical compound called 1-phenyl-2-thiourea (PTU) is commonly used to suppress pigment formation in ... years, the PolyU research team led by Dr MA has been using the ...
(Date:7/7/2020)... (PRWEB) , ... July 06, 2020 , ... ... Practices Awards. Entries from Roche, Eli Lilly, Bristol-Myers Squibb, the University of Chicago, ... 2003, Bio-IT World has hosted an elite awards program, highlighting outstanding examples of ...
(Date:7/1/2020)... ... June 30, 2020 , ... ... the launch of a new clinical diagnostics immuno-oncology service, TissueInsight . ... (TME). , “Flagship’s TissueInsight is a service that aids pathologists, oncologists, and ...
(Date:6/28/2020)... HILL, Conn. (PRWEB) , ... June 25, 2020 ... ... company formed to advance photodynamic therapy for treating cancer, today announced the company ... New York (“Roswell Park”). The agreement provides Lumeda globally exclusive rights to ...
Breaking Biology Technology:
Cached News: